CN102805868A - 用配体-免疫原缀合物治疗的方法 - Google Patents

用配体-免疫原缀合物治疗的方法 Download PDF

Info

Publication number
CN102805868A
CN102805868A CN2012102411983A CN201210241198A CN102805868A CN 102805868 A CN102805868 A CN 102805868A CN 2012102411983 A CN2012102411983 A CN 2012102411983A CN 201210241198 A CN201210241198 A CN 201210241198A CN 102805868 A CN102805868 A CN 102805868A
Authority
CN
China
Prior art keywords
immunogen
ligand
host
cell
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2012102411983A
Other languages
English (en)
Chinese (zh)
Inventor
P·S·罗
Y·卢
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of CN102805868A publication Critical patent/CN102805868A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN2012102411983A 2000-03-31 2001-03-30 用配体-免疫原缀合物治疗的方法 Pending CN102805868A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US19394400P 2000-03-31 2000-03-31
US60/193944 2000-03-31
US25584600P 2000-12-15 2000-12-15
US60/255846 2000-12-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN018101852A Division CN1441676B (zh) 2000-03-31 2001-03-30 用配体-免疫原缀合物治疗的方法

Publications (1)

Publication Number Publication Date
CN102805868A true CN102805868A (zh) 2012-12-05

Family

ID=26889531

Family Applications (2)

Application Number Title Priority Date Filing Date
CN018101852A Expired - Fee Related CN1441676B (zh) 2000-03-31 2001-03-30 用配体-免疫原缀合物治疗的方法
CN2012102411983A Pending CN102805868A (zh) 2000-03-31 2001-03-30 用配体-免疫原缀合物治疗的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN018101852A Expired - Fee Related CN1441676B (zh) 2000-03-31 2001-03-30 用配体-免疫原缀合物治疗的方法

Country Status (20)

Country Link
US (2) US7033594B2 (enExample)
EP (1) EP1267918A4 (enExample)
JP (2) JP5059271B2 (enExample)
KR (1) KR100863632B1 (enExample)
CN (2) CN1441676B (enExample)
AU (2) AU5697001A (enExample)
BR (1) BR0109704A (enExample)
CA (1) CA2405299C (enExample)
CZ (1) CZ304942B6 (enExample)
DZ (1) DZ3332A1 (enExample)
EA (1) EA005823B1 (enExample)
HR (1) HRP20020787B1 (enExample)
HU (1) HUP0300421A2 (enExample)
IL (2) IL151927A0 (enExample)
MX (1) MXPA02009454A (enExample)
NO (1) NO332160B1 (enExample)
NZ (1) NZ521898A (enExample)
PL (1) PL211872B1 (enExample)
SK (1) SK288201B6 (enExample)
WO (1) WO2001074382A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108051581A (zh) * 2017-12-18 2018-05-18 河北中医学院 非共价键连接法半抗原---载体免疫原的制备

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US7192698B1 (en) 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US7645743B2 (en) * 1999-12-22 2010-01-12 Altermune, Llc Chemically programmable immunity
CA2328356A1 (en) * 1999-12-22 2001-06-22 Itty Atcravi Recreational vehicles
AU5697001A (en) 2000-03-31 2001-10-15 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
US7875612B2 (en) 2001-04-24 2011-01-25 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
RU2316349C2 (ru) 2001-05-02 2008-02-10 Пердью Рисерч Фаундейшн Лечение и диагностика заболеваний, опосредованных макрофагами
EP1434603B1 (en) * 2001-09-28 2009-12-16 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
AU2002337954C1 (en) * 2001-10-22 2008-10-23 The Scripps Research Institute Integrin targeting compounds
US8043603B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8043602B2 (en) * 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
AU2003224989B2 (en) 2002-04-19 2008-12-04 Endocyte, Inc. Adjuvant enhanced immunotherapy
WO2004014292A2 (en) * 2002-05-10 2004-02-19 Purdue Research Foundation EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF
JP4557714B2 (ja) * 2002-05-10 2010-10-06 メディミューン，エルエルシー ＥｐｈＡ２モノクローナル抗体およびその使用法
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
DE60326833D1 (de) * 2002-05-15 2009-05-07 Endocyte Inc Vitamin-mitomycin-konjugate
AR042942A1 (es) * 2003-01-27 2005-07-06 Endocyte Inc Conjugados de administracion de drogas de union de receptores de vitaminas
EP1594898A2 (en) 2003-02-06 2005-11-16 Tripep AB Glycosylated specificity exchangers
EP1617864A4 (en) * 2003-04-11 2006-06-21 Medimmune Inc EPHA2 AND NON-NEOPLASTIC HYPERPROLIFERATIVE CELL TROUBLESHOOTING
US20060204565A1 (en) * 2003-05-06 2006-09-14 Low Philip S Conjugates and use thereof
DE602004017452D1 (de) 2003-05-30 2008-12-11 Purdue Research Foundation Diagnoseverfahren für atherosklerose
WO2005046730A2 (en) * 2003-11-12 2005-05-26 The University Of Georgia Research Foundation, Inc. Biotin-facilitated transport into gram negative bacteria
US20080112977A1 (en) * 2004-07-03 2008-05-15 Mogam Biotechnology Research Supertype Epitopes, Oligonucleotides Coding The Same Which Induce Effective Ctl Response Against Hcv And The Use Thereof
US7785875B2 (en) 2004-07-03 2010-08-31 Mogam Biotechnology Research Institute Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same
CN101098854B (zh) 2004-07-23 2012-12-05 恩多塞特公司 二价连接体及其轭合物
JP2008525485A (ja) * 2004-12-23 2008-07-17 パーデュー・リサーチ・ファウンデーション ポジトロン放射断層画像法
CN101175757B (zh) * 2005-03-16 2012-11-14 恩多塞特公司 蝶酸及其缀合物的合成和纯化
WO2006105141A1 (en) * 2005-03-30 2006-10-05 Purdue Research Foundation Method for cancer prognosis using cellular folate vitamin receptor quantification
WO2007006041A2 (en) 2005-07-05 2007-01-11 Purdue Research Foundation Imaging and therapeutic method using monocytes
WO2007022493A2 (en) * 2005-08-19 2007-02-22 Endocyte, Inc. Ligand conjugates of vinca alkaloids, analogs, and derivatives
EP2374480A3 (en) 2005-08-19 2013-05-01 Endocyte, Inc. Mutli-drug ligand conjugates
US8795633B2 (en) 2005-09-23 2014-08-05 Purdue Research Foundation Multiphoton in vivo flow cytometry method and device
WO2007056525A2 (en) * 2005-11-10 2007-05-18 James Paulson High affinity siglec ligands
WO2007092299A2 (en) 2006-02-03 2007-08-16 Purdue Research Foundation Targeted conjugates and radiation
US20100226967A1 (en) * 2006-05-23 2010-09-09 Purdue Research Foundation Imaging and therapeutic method using progenitor cells
US8486412B2 (en) 2006-06-01 2013-07-16 Mayo Foundation For Medical Education And Research Immunity to folate receptors
EP2087337A4 (en) 2006-11-03 2010-09-08 Purdue Research Foundation METHOD AND DEVICE FOR EX-VIVO FLOW CYTOMETRY
CA2677792C (en) 2007-02-07 2015-04-14 Purdue Research Foundation Positron emission tomography imaging method
WO2008101231A2 (en) 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
NZ599239A (en) 2007-03-14 2013-10-25 Endocyte Inc Binding ligand linked drug delivery conjugates of tubulysins
EP2164525A2 (en) 2007-05-25 2010-03-24 Purdue Research Foundation Method of imaging localized infections
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
US9138484B2 (en) 2007-06-25 2015-09-22 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
PL2187965T3 (pl) 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
DK2199390T3 (en) 2007-08-30 2017-04-03 Daiichi Sankyo Co Ltd ANTI-EphA2 ANTIBODY
US9187521B2 (en) 2007-10-25 2015-11-17 Endocyte, Inc. Tubulysins and processes for preparing
CA2705808A1 (en) * 2007-11-15 2009-05-22 Endocyte, Inc. Method of administering conjugates
DK2291659T3 (en) * 2008-05-13 2015-12-21 Univ Yale SMALL CHEMICAL MOLECULES FOR RECRUITING ANTIBODIES TO CANCER CELLS
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
WO2010129666A1 (en) * 2009-05-05 2010-11-11 Altermune Technologies, Llc Chemically programmable immunity
SMT201700139T1 (it) 2010-02-24 2017-05-08 Immunogen Inc Immunoconiugati contro il recettore 1 del folato e relativi usi
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
CN103037903A (zh) 2010-05-18 2013-04-10 天蓝制药公司 用于治疗自身免疫性疾病或其它疾病的组合物和方法
CN114441757A (zh) 2011-04-01 2022-05-06 伊缪诺金公司 用于增加folr1癌症治疗的功效的方法
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
US9629918B2 (en) 2012-02-29 2017-04-25 Purdue Research Foundation Folate receptor alpha binding ligands
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
MX362514B (es) 2012-08-31 2019-01-22 Immunogen Inc Kits y ensayos de diagnostico para la deteccion del receptor 1 de folato.
US9662402B2 (en) 2012-10-16 2017-05-30 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
KR102575825B1 (ko) 2012-11-15 2023-09-06 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
ES2949648T3 (es) 2012-12-20 2023-10-02 Purdue Research Foundation Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer
BR112015022810B1 (pt) 2013-03-15 2021-11-30 Purdue Research Foundation Composto, composição e método para identificar tipo de célula alvo em amostra biológica
US20170232119A1 (en) 2013-03-15 2017-08-17 Purdue Research Foundation Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
SG11201601037YA (en) 2013-08-30 2016-03-30 Immunogen Inc Antibodies and assays for detection of folate receptor 1
MY194484A (en) 2013-10-18 2022-11-30 Deutsches Krebsforsch Labeled Inhibitors of Prostate Specific Membrane Antigen (PSMA), Their use as Imaging Agents and Pharmaceutical Agents for the Treatment of Prostate Cancer
MX2016006219A (es) 2013-11-14 2016-10-28 Endocyte Inc Compuestos para tomografia por emision de positrones.
GB201411150D0 (en) 2014-06-23 2014-08-06 Altermune Technologies Llc Novel aptamers and therapeutic uses thereof
EP3186282A1 (en) * 2014-08-28 2017-07-05 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
JP6880006B2 (ja) 2015-09-17 2021-06-02 イミュノジェン， インコーポレイテッド 抗ｆｏｌｒ１免疫複合体を含む治療組み合わせ
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Ｃａｒ ｔ細胞療法のための方法および組成物
US20180067121A1 (en) * 2016-09-06 2018-03-08 Nanoco Technologies Ltd. Exosome-conjugated quantum dot nanoparticles and methods of detecting exosomes and cancer using same
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN110612119B (zh) 2017-02-07 2024-10-29 西雅图儿童医院（Dba西雅图儿童研究所） 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂
US11850262B2 (en) 2017-02-28 2023-12-26 Purdue Research Foundation Compositions and methods for CAR T cell therapy
JP6990522B2 (ja) 2017-04-11 2022-02-03 シスメックス株式会社 免疫細胞の免疫刺激応答性を測定する方法、免疫細胞における免疫シナプスの形成能を判定する方法及び細胞分析装置
BR112020014913A2 (pt) 2018-01-22 2020-12-08 Seattle Children's Hospital (dba Seattle Children's Research Institute) Métodos para uso de células t car
SG11202007426XA (en) 2018-02-06 2020-09-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
CA3091674A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
KR20210003135A (ko) 2018-04-17 2021-01-11 엔도사이트, 인코포레이티드 암의 치료 방법
WO2020236808A1 (en) 2019-05-20 2020-11-26 Endocyte, Inc. Methods for preparing psma conjugates

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996036367A1 (en) * 1995-05-16 1996-11-21 Purdue Research Foundation Composition and method for tumor imaging
WO2000010599A2 (en) * 1998-08-19 2000-03-02 North American Vaccine, Inc. IMMUNOGENIC β-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2816110A (en) * 1956-11-23 1957-12-10 Merck & Co Inc Methods for the production of substituted pteridines
US4314988A (en) 1979-10-31 1982-02-09 Baker Instruments Corp. Folic acid derivatives and process for preparation
US4713249A (en) * 1981-11-12 1987-12-15 Schroeder Ulf Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof
US4659655A (en) * 1981-11-25 1987-04-21 Bio-Response, Inc. Method for isolating product-producing cells
US5140104A (en) * 1982-03-09 1992-08-18 Cytogen Corporation Amine derivatives of folic acid analogs
JP2534222B2 (ja) 1982-05-12 1996-09-11 プレジデント アンド フエロウズ オブ ハ−バ−ド カレツジ 混成タンパク質生産用融合遺伝子
NL8401226A (nl) 1984-04-16 1985-11-18 Univ Utrecht Farmaceutisch produkt met anti-tumorwerking; gebruik van een farmaceutisch produkt of van farmaceutische samenstellingen in een anti-tumortherapie.
ATE74622T1 (de) 1984-10-31 1992-04-15 Massachusetts Inst Technology Verfahren zum sensibilisieren einer zielzelle zum lysen durch cytotoxische t-lymphkoerperchen.
US5266333A (en) * 1985-03-06 1993-11-30 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone
US4681760A (en) 1985-04-17 1987-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of conferring immunotolerance to a specific antigen
CA1282069C (en) * 1985-09-12 1991-03-26 Damon L. Meyer Antibody complexes of hapten-modified diagnostic or therapeutic agents
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
NZ217821A (en) 1985-10-10 1989-07-27 Biotech Australia Pty Ltd Oral delivery system; complex of active agent and vitamin b12 or analogue thereof
US5117022A (en) * 1985-10-18 1992-05-26 The Board Of Regents, The University Of Texas System Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
JPS6479125A (en) 1986-08-13 1989-03-24 Takeda Chemical Industries Ltd Antitumor agent
GB8626413D0 (en) 1986-11-05 1986-12-03 Gilliland L K Antibodies
US5888512A (en) 1987-01-30 1999-03-30 Board Of Trustees Of The Leland Stanford Junior University Lymphocyte activity regulation by HLA peptides
US4971792A (en) 1987-03-27 1990-11-20 The Wistar Institute Monoclonal antibodies against glycolipid antigens
US5583112A (en) 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4946945A (en) 1987-06-23 1990-08-07 Allergy Immuno Technologies, Inc. Immunotherapy agents for treatment of IgE mediated allergies
DE3880766D1 (de) 1987-09-02 1993-06-09 Ciba Geigy Ag Konjugate von interferon alpha mit immunglobulinen.
DK8189A (da) 1988-01-12 1989-07-13 Bunge Australia Antigen-antistof-konjugater, deres fremstilling og anvendelse
GB8803365D0 (en) 1988-02-13 1988-03-16 Ciba Geigy Ag Antiviral combination
EP0334300A1 (en) 1988-03-21 1989-09-27 Neorx Corporation The use of monoclonal antibodies and conjugates thereof as signals to direct sensitized effector cells to tumor sites
DE3825615A1 (de) 1988-07-28 1990-02-01 Behringwerke Ag Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
EP0369387B1 (en) 1988-11-14 1996-05-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Spherical vinyl chloride resin granules and process for producing the same
JPH02169521A (ja) 1988-12-22 1990-06-29 Ajinomoto Co Inc 自己免疫疾患治療剤
EP0460076B1 (en) 1989-02-24 1995-11-29 The Regents Of The University Of California Genetically engineered immunoglobulins
US5075287A (en) 1989-03-03 1991-12-24 Nisshin Oil Mills, Inc. Muramyl peptide derivatives and immunoregulating compositions containing them
GB8907310D0 (en) 1989-03-31 1989-05-17 Medical Res Council Heteroconjugates
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5217881A (en) 1989-04-25 1993-06-08 Immunex Corporation Hyperglycosylated cytokine conjugates
JPH04501808A (ja) 1989-07-06 1992-04-02 セラジェン・インコーポレーテッド ハイブリッド分子
FI920131A0 (fi) 1989-07-14 1992-01-13 Praxis Biolog Inc Cytokin- och hormonbaerare foer konjugatvaccin.
JP2807831B2 (ja) 1989-07-18 1998-10-08 国際試薬株式会社 免疫学的測定法
JPH0686375B2 (ja) 1989-09-25 1994-11-02 大塚製薬株式会社 リポソーム製剤
KR910009284A (ko) 1989-11-13 1991-06-28 원본미기재 인체 종양 세포 항원에 특이적인 키메라형 생쥐-인체 a10 항체
ES2171392T3 (es) 1990-08-29 2002-09-16 Ct Hospitalier Regional De Nan Poliligandos de proteina unidos a un nucleo de proteina estable.
JP3105629B2 (ja) 1991-04-23 2000-11-06 サングスタット メディカル コーポレイション 特異的結合ペアのメンバーの細胞活性調節接合体
IT1244983B (it) 1991-04-29 1994-09-13 Raggio Italgene Spa Procedimento per rivelare sequenze di acidi nucleici e kit per la sua utilizzazione.
JP3173814B2 (ja) 1991-05-30 2001-06-04 株式会社タムラ製作所 フラックス塗布方法
US6335434B1 (en) * 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
US5159079A (en) * 1991-12-20 1992-10-27 Eli Lilly And Company 2-piperidones as intermediates for 5-deaza-10-oxo- and 5-deaza-10-thio-5,6,7,8-tetrahydrofolic acids
US5273965A (en) 1992-07-02 1993-12-28 Cambridge Biotech Corporation Methods for enhancing drug delivery with modified saponins
US5650398A (en) 1992-07-02 1997-07-22 Cambridge Biotech Corporation Drug delivery enhancement via modified saponins
DE69306545T2 (de) 1992-10-01 1997-04-03 Wellcome Found Tucaresol als Mittel zur Immunopotentierung
DE4238416A1 (de) 1992-11-13 1994-05-19 Max Planck Gesellschaft Bestimmung von Peptidmotiven auf MHC-Molekülen
US5747024A (en) 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
ES2187520T3 (es) 1993-03-19 2003-06-16 Vacsyn Sa Composiciones para aplicacion en terapeutica humana, caracterizadas por la asociacion de un muramil-peptido a una citoquina.
US5482698A (en) 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
JP3785187B2 (ja) 1993-07-14 2006-06-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 樹枝状体ポリ陽イオンを含む自己集合性ポリヌクレオチド配送系
US5834441A (en) 1993-09-13 1998-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral (AAV) liposomes and methods related thereto
CN1044781C (zh) * 1994-02-05 1999-08-25 丹东市生物制品免疫技术应用研究中心 复方免疫抗生素
US5417982A (en) * 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
JP2660661B2 (ja) 1994-05-11 1997-10-08 株式会社バイオセンサー研究所 遺伝子の定量方法
WO1995034321A1 (en) 1994-06-16 1995-12-21 The Board Of Trustees Of The Leland Stanford Junior University Immune modulation with class ii alpha-chain fragments
US5547668A (en) * 1995-05-05 1996-08-20 The Board Of Trustees Of The University Of Illinois Conjugates of folate anti-effector cell antibodies
US5753625A (en) 1995-05-12 1998-05-19 Sangstat Medical Corporation Treatment for inhibiting the progression of autoimmune disease
US5602171A (en) * 1995-06-07 1997-02-11 Sugen Inc. Methods of inhibiting phosphatase activity and treatment of disorders associated therewith using naphthopyrones and derivatives thereof
WO1997024140A1 (en) 1996-01-02 1997-07-10 The Board Of Trustees Of Leland Stanford Junior University Interaction of hla proteins with members of the hsp70 family of proteins
US6509313B1 (en) * 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
JPH10511989A (ja) 1996-04-10 1998-11-17 サングスタット メディカル コーポレイション 特異的結合ペア構成要素の細胞調節性複合体
US6231859B1 (en) 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
ES2235330T3 (es) 1997-05-20 2005-07-01 Galenica Pharmaceuticals, Inc. Analogos de saponionas triterpenicas que tienen actividad ayuvante.
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
US6291673B1 (en) 1997-10-17 2001-09-18 Purdue Research Foundation Folic acid derivatives
DE19746173A1 (de) * 1997-10-18 1999-04-22 Boehringer Ingelheim Int Tumorvakzine
US6262029B1 (en) 1998-08-14 2001-07-17 Galenica Pharmaceuticals, Inc. Chemically modified saponins and the use thereof as adjuvants
WO2001032207A1 (en) * 1998-10-30 2001-05-10 United States Army Medical Research And Materiel Command Methods for conferring active/passive immunotherapy
AUPQ071299A0 (en) 1999-06-02 1999-06-24 Access Pharmaceuticals Australia Pty Limited Vitamin directed dual targeting therapy
ES2357296T3 (es) 1999-08-17 2011-04-25 Purdue Research Foundation Anticuerpos dirigidos contra epha2 como un diagnóstico de cáncer.
PT1242060E (pt) 1999-08-17 2006-08-31 Glaxo Group Ltd Tratamento da doenca metastatica
WO2001047552A1 (en) 1999-09-08 2001-07-05 Sloane-Kettering Institute For Cancer Research Polysialic acid-klh conjugate vaccine
UA77152C2 (en) 1999-09-25 2006-11-15 Method for stimulation of immune response using nucleic acid-containing immunostimulating compositions, method for treatment of cancer and method for treatment or prophylaxis of allergy or asthma
AU783118B2 (en) 1999-09-27 2005-09-29 Coley Pharmaceutical Gmbh Methods related to immunostimulatory nucleic acid-induced interferon
US20020039583A1 (en) 1999-09-30 2002-04-04 Subjeck John R. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
AU781812B2 (en) 2000-01-13 2005-06-16 Antigenics, Inc. Innate immunity-stimulating compositions of CPG and saponin and methods thereof
AU5697001A (en) 2000-03-31 2001-10-15 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
EP1434603B1 (en) 2001-09-28 2009-12-16 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
AU2003224989B2 (en) 2002-04-19 2008-12-04 Endocyte, Inc. Adjuvant enhanced immunotherapy
AR042942A1 (es) 2003-01-27 2005-07-06 Endocyte Inc Conjugados de administracion de drogas de union de receptores de vitaminas
US20050222068A1 (en) 2003-10-23 2005-10-06 Mourich Dan V Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells
WO2007092299A2 (en) 2006-02-03 2007-08-16 Purdue Research Foundation Targeted conjugates and radiation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996036367A1 (en) * 1995-05-16 1996-11-21 Purdue Research Foundation Composition and method for tumor imaging
WO2000010599A2 (en) * 1998-08-19 2000-03-02 North American Vaccine, Inc. IMMUNOGENIC β-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRYAN K.CHO，ET.AL: "Single-Chain Fv/Folate Conjugates Mediate Efficient Lysis of Folate-Receptor-Positive Tumor Cells", 《BIOCONJUGATE CHEM.》 *
CHRISTOPHER M.WARD，ET.AL: "Folic Acid Targeting of Protein Conjugates into Ascites Tumour Cells from Ovarian Cancer Patients", 《JOURNAL OF DRUG TARGETING》 *
DAVID M. KRANZ，ET.AL: "Conjugates of folate and anti-T-cell-receptor antibodies specifically target folate-receptor-positive tumor cells for lysis", 《PROC.NATL.ACAD.SCI.USA》 *
JOSEPH A.REDDY,ET.AL: "Folate-Mediated Targeting of Therapeutic and Imaging Agents to Cancers", 《CRITICAL REVIEW IN THERAPEUTIC DRUG CARRIER SYSTEM》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108051581A (zh) * 2017-12-18 2018-05-18 河北中医学院 非共价键连接法半抗原---载体免疫原的制备

Also Published As

Publication number Publication date
US8105608B2 (en) 2012-01-31
CZ20023240A3 (cs) 2003-10-15
CN1441676B (zh) 2012-08-22
KR100863632B1 (ko) 2008-10-15
JP5632813B2 (ja) 2014-11-26
US7033594B2 (en) 2006-04-25
AU5697001A (en) 2001-10-15
CZ304942B6 (cs) 2015-02-04
MXPA02009454A (es) 2003-04-10
DZ3332A1 (fr) 2001-10-11
CA2405299A1 (en) 2001-10-11
JP2012092097A (ja) 2012-05-17
WO2001074382A1 (en) 2001-10-11
US20060067946A1 (en) 2006-03-30
HRP20020787A2 (en) 2004-02-29
PL357943A1 (en) 2004-08-09
SK288201B6 (sk) 2014-06-03
JP5059271B2 (ja) 2012-10-24
HRP20020787B1 (hr) 2012-06-30
EA005823B1 (ru) 2005-06-30
WO2001074382A9 (en) 2002-10-10
AU2001256970C1 (en) 2008-07-03
CA2405299C (en) 2014-07-22
NO20024577D0 (no) 2002-09-24
IL213240A (en) 2015-04-30
EP1267918A1 (en) 2003-01-02
SK13962002A3 (sk) 2004-02-03
US20010031252A1 (en) 2001-10-18
JP2003528924A (ja) 2003-09-30
NO20024577L (no) 2002-11-05
NZ521898A (en) 2004-11-26
IL213240A0 (en) 2011-07-31
BR0109704A (pt) 2003-04-29
AU2001256970B2 (en) 2007-06-14
IL151927A0 (en) 2003-04-10
CN1441676A (zh) 2003-09-10
EA200201042A1 (ru) 2003-04-24
KR20020087431A (ko) 2002-11-22
HUP0300421A2 (hu) 2003-06-28
NO332160B1 (no) 2012-07-09
EP1267918A4 (en) 2007-06-27
PL211872B1 (pl) 2012-07-31

Similar Documents

Publication Publication Date Title
CN102805868A (zh) 用配体-免疫原缀合物治疗的方法
CN1662251B (zh) 佐剂增强的免疫应用
AU2001256970A1 (en) Method of treatment using ligand-immunogen conjugates
JP2005523878A (ja) リガンド・免疫原物質複合体を用いた処置方法
JP5554713B2 (ja) 接合体を投与する方法
HK1179518A (en) Method of treatment using ligand-immunogen conjugates
KR20050016350A (ko) 어쥬번트 보강된 면역요법
ZA200207768B (en) Method of treatment using ligand-immunogen conjugates.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1179518

Country of ref document: HK

AD01 Patent right deemed abandoned

Effective date of abandoning: 20160120

C20 Patent right or utility model deemed to be abandoned or is abandoned
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1179518

Country of ref document: HK